Laura Puzniak

3.2k total citations · 2 hit papers
105 papers, 1.9k citations indexed

About

Laura Puzniak is a scholar working on Infectious Diseases, Epidemiology and Applied Microbiology and Biotechnology. According to data from OpenAlex, Laura Puzniak has authored 105 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Infectious Diseases, 33 papers in Epidemiology and 31 papers in Applied Microbiology and Biotechnology. Recurrent topics in Laura Puzniak's work include Antibiotic Use and Resistance (31 papers), SARS-CoV-2 and COVID-19 Research (28 papers) and COVID-19 Clinical Research Studies (23 papers). Laura Puzniak is often cited by papers focused on Antibiotic Use and Resistance (31 papers), SARS-CoV-2 and COVID-19 Research (28 papers) and COVID-19 Clinical Research Studies (23 papers). Laura Puzniak collaborates with scholars based in United States, United Kingdom and Japan. Laura Puzniak's co-authors include Marin H. Kollef, Linda M. Mundy, John M. McLaughlin, Luis Jódar, Sanjay Merchant, Terry Leet, Sara Y. Tartof, Kathleen N. Gillespie, Jeffrey Chan and Gowri Raman and has published in prestigious journals such as JAMA, Nature Communications and Gastroenterology.

In The Last Decade

Laura Puzniak

98 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Seasonal trends in COVID-19 cases, hospitalizations, and mortality in the United States and Europe

2023 83 citations Timothy L. Wiemken, Farid Khan et al. profile →
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system

2023 74 citations John M. McLaughlin, Laura Puzniak et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura Puzniak United States	22	1.1k	522	480	441	298	105	1.9k
Khetam Hussein Israel	20	636 0.6×	680 1.3×	442 0.9×	336 0.8×	272 0.9×	60	1.7k
James A. McKinnell United States	27	1.3k 1.2×	495 0.9×	806 1.7×	333 0.8×	278 0.9×	81	2.5k
Brigid Wilson United States	25	730 0.7×	594 1.1×	481 1.0×	257 0.6×	239 0.8×	155	2.2k
Kyungmin Huh South Korea	24	945 0.9×	258 0.5×	621 1.3×	180 0.4×	148 0.5×	152	2.0k
Angelo Pan Italy	24	1.1k 1.0×	527 1.0×	550 1.1×	409 0.9×	172 0.6×	69	2.2k
Sujan Reddy United States	19	561 0.5×	306 0.6×	377 0.8×	296 0.7×	117 0.4×	62	1.7k
Alice Guh United States	22	1.3k 1.2×	244 0.5×	1000 2.1×	130 0.3×	100 0.3×	66	2.2k
Noa Eliakim‐Raz Israel	26	686 0.6×	212 0.4×	830 1.7×	135 0.3×	148 0.5×	72	1.8k
Young Kyung Yoon South Korea	25	692 0.7×	313 0.6×	595 1.2×	291 0.7×	143 0.5×	125	1.7k
Kelly M Hatfield United States	14	691 0.7×	338 0.6×	393 0.8×	298 0.7×	154 0.5×	41	1.7k

Countries citing papers authored by Laura Puzniak

Since Specialization

Citations

This map shows the geographic impact of Laura Puzniak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Puzniak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Puzniak more than expected).

Fields of papers citing papers by Laura Puzniak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Puzniak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Puzniak. The network helps show where Laura Puzniak may publish in the future.

Co-authorship network of co-authors of Laura Puzniak

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Puzniak. A scholar is included among the top collaborators of Laura Puzniak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Puzniak. Laura Puzniak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caffrey, Aisling R., Haley J. Appaneal, Vrishali V. Lopes, et al.. (2025). Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19. Microbiology Spectrum. 13(4). e0320924–e0320924. 1 indexed citations

Andersen, Kathleen M., et al.. (2025). 2024–2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims. Vaccine. 62. 127534–127534.

Appaneal, Haley J., Vrishali V. Lopes, Laura Puzniak, et al.. (2025). Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System. Nature Communications. 16(1). 4033–4033. 4 indexed citations

Appaneal, Haley J., Kerry L. LaPlante, Vrishali V. Lopes, et al.. (2024). Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System. Infectious Diseases and Therapy. 13(1). 155–172. 8 indexed citations

Tartof, Sara Y., Jeff Slezak, Laura Puzniak, et al.. (2024). Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages. Open Forum Infectious Diseases. 11(7). ofae370–ofae370. 7 indexed citations

Caffrey, Aisling R., Haley J. Appaneal, Vrishali V. Lopes, et al.. (2024). Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System. Nature Communications. 15(1). 9490–9490. 12 indexed citations

Penrose, Kate, Yanhan Shen, McKaylee Robertson, et al.. (2024). Perceived Risk for Severe COVID-19 and Oral Antiviral Use Among Antiviral-Eligible US Adults. Infectious Diseases and Therapy. 13(8). 1743–1757.

Fusco, Manuela Di, Xiaowu Sun, Kristen E. Allen, et al.. (2023). Impact of Bivalent BA.4/5 BNT162b2 COVID-19 Vaccine on Acute Symptoms, Quality of Life, Work Productivity and Activity Levels among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy. Vaccines. 11(11). 1669–1669. 5 indexed citations

Rudolph, Abby E., Farid Khan, Tanya Singh, et al.. (2023). Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy. The Journal of Infectious Diseases. 229(3). 648–659. 6 indexed citations

10.

Puzniak, Laura, et al.. (2023). A multicenter evaluation of antibacterial use in hospitalized patients through the SARS-Cov-2 pandemic waves. BMC Infectious Diseases. 23(1). 117–117. 1 indexed citations

11.

Caffrey, Aisling R., et al.. (2022). Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia. Antibiotics. 11(8). 1033–1033. 4 indexed citations

12.

Caffrey, Aisling R., et al.. (2022). The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections. Antibiotics. 11(5). 626–626. 7 indexed citations

13.

Goodman, Katherine E, Jonathan Baghdadi, Laurence S. Magder, et al.. (2022). Patterns, Predictors, and Intercenter Variability in Empiric Gram-Negative Antibiotic Use Across 928 United States Hospitals. Clinical Infectious Diseases. 76(3). e1224–e1235. 17 indexed citations

14.

Appaneal, Haley J., et al.. (2022). Assessing Rates of Co-Resistance and Patient Outcomes in Multidrug-Resistant Pseudomonas aeruginosa. Microbiology Spectrum. 10(5). e0233622–e0233622. 3 indexed citations

15.

Tran, Truc T., Anne J Gonzales-Luna, Travis J Carlson, et al.. (2022). Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA. JAC-Antimicrobial Resistance. 5(1). dlac131–dlac131. 3 indexed citations

16.

Zilberberg, Marya D., Brian H. Nathanson, Laura Puzniak, & Andrew F. Shorr. (2022). Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014–2019. Infection Control and Hospital Epidemiology. 43(3). 277–283. 12 indexed citations

17.

Puzniak, Laura, et al.. (2021). 1282. Ceftolozane/Tazobactam Use in Critically Ill Patients Receiving Intermittent or Continuous Renal Replacement Therapy. Open Forum Infectious Diseases. 8(Supplement_1). S730–S730. 1 indexed citations

18.

Duane, Therèse M., Blair Capitano, Laura Puzniak, Pinaki Biswas, & Manjari Joshi. (2013). The Impact of Linezolid versus Vancomycin on Surgical Interventions for Complicated Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus. Surgical Infections. 14(4). 401–407. 6 indexed citations

19.

Duane, Therèse M., John A. Weigelt, Laura Puzniak, & David B. Huang. (2012). Linezolid and Vancomycin in Treatment of Lower-Extremity Complicated Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus in Patients with and without Vascular Disease. Surgical Infections. 13(3). 147–153. 12 indexed citations

20.

Bonilla, Hector, Michael D. Huband, Helen Schmidt, et al.. (2010). Multicity Outbreak of Linezolid‐ResistantStaphylococcus epidermidisAssociated with Clonal Spread of acfr‐Containing Strain. Clinical Infectious Diseases. 51(7). 796–900. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact